Covidien snaps up Reverse Medical and its line of vascular devices for an unspecified amount.
Some of Medtronic's shareholders aren't pleased about the structure of the $43 billion mega-merger with Covidien, which will stick some long-time backers with significant fees.
Covidien says it plans to get its recalled Pipeline brain embolism device back on the market immediately, after the FDA approved manufacturing changes aimed at correcting the problem that prompted the recall.
Here's a look at some of the top Wall Street stories for medical device companies this week: Will Medtronic follow Walgreen and abandon inversion in Covidien deal?; ElectroCore seeks commercial partners for non-invasive headache tech; Allergan-Valeant update: SEC launches Ackman probe, Allergan pays up to $588M for Liris bladder drug, Ackman dangles IPO; Activist investor battles on over ConMed as shareholders vote approaches; Medtronic's Q1 earnings beat The Street on modest sales bump
Covidien launches 1st-of-its-kind Center of Innovation in CEO Jose Almeida's home country of Brazil.
MASSDEVICE ON CALL — Medtech titan Covidien (NYSE:COV) cut the ribbon on a new training center in Sao Paulo, Brazil, the home country of president & CEO Jose Almeida.
Final results from Covidien's DEFINITIVE LE study, originally closed in 2012, finally appear in the Journal of American College of Cardiology, Cardiovascular Interventions.
It may have taken 2 years but final results from Covidien's (NYSE:COV) DEFINITIVE LE study finally appeared in the Journal of the American College of Cardiology's Cardiovascular Interventions issue.
Here's a look at some of the top regulatory stories for medical device companies this week: Amid political noise, Ishrak seeks to reassure employees on Medtronic-Covidien deal; Will Medtronic follow Walgreen and abandon inversion in Covidien deal?; Medtronic founder Bakken backs Covidien buy; Allergan-Valeant update: SEC launches Ackman probe, Allergan pays up to $588M for Liris bladder drug, Ackman dangles IPO; Allergan CFO Edwards steps down amid hostile Valeant takeover bid
, Biolase Technology Inc.
, Insulet Corp.
, Monarch Medical
, Pershing Square Capital Management
, Trinity Medical
, Valeant Pharmaceuticals
, Volpara Solutions
, Allergan Inc.